Pau Montesinos

17.0k total citations · 2 hit papers
309 papers, 5.3k citations indexed

About

Pau Montesinos is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Pau Montesinos has authored 309 papers receiving a total of 5.3k indexed citations (citations by other indexed papers that have themselves been cited), including 263 papers in Hematology, 131 papers in Molecular Biology and 76 papers in Genetics. Recurrent topics in Pau Montesinos's work include Acute Myeloid Leukemia Research (211 papers), Chronic Myeloid Leukemia Treatments (71 papers) and Acute Lymphoblastic Leukemia research (70 papers). Pau Montesinos is often cited by papers focused on Acute Myeloid Leukemia Research (211 papers), Chronic Myeloid Leukemia Treatments (71 papers) and Acute Lymphoblastic Leukemia research (70 papers). Pau Montesinos collaborates with scholars based in Spain, United States and Italy. Pau Montesinos's co-authors include Miguel Á. Sanz, David Martínez‐Cuadrón, Juan Eduardo Megías‐Vericat, Jaime Sanz, Guillermo Sanz, Salut Brunet, Federico Moscardó, Michael Heuser, Juan Bergua and Jordi Esteve and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Pau Montesinos

292 papers receiving 5.3k citations

Hit Papers

Randomized comparison of low dose cytarabine with or with... 2018 2026 2020 2023 2018 2022 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
    2018 354 citations Jörge E. Cortes, Tadeusz Robak et al. Leukemia profile →
  2. Ivosidenib and Azacitidine in IDH1 -Mutated Acute Myeloid Leukemia
    2022 295 citations Pau Montesinos, Christian Récher et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Pau Montesinos Spain 35 3.8k 2.8k 1.1k 996 789 309 5.3k
Vikram Mathews India 36 2.6k 0.7× 1.6k 0.6× 678 0.6× 702 0.7× 877 1.1× 293 4.0k
Lionel Adès France 41 4.0k 1.1× 2.1k 0.8× 915 0.8× 637 0.6× 1.5k 1.9× 219 5.6k
Giuseppe Avvisati Italy 43 5.0k 1.3× 4.1k 1.5× 1.5k 1.4× 987 1.0× 922 1.2× 202 7.5k
E Archimbaud France 34 3.3k 0.9× 2.3k 0.8× 1.4k 1.2× 1.1k 1.1× 616 0.8× 124 5.1k
R Ohno Japan 33 4.1k 1.1× 2.2k 0.8× 1.2k 1.0× 1.3k 1.3× 1.1k 1.5× 104 5.7k
Stéphane de Botton France 44 4.1k 1.1× 3.0k 1.1× 1.2k 1.1× 997 1.0× 1.3k 1.7× 201 6.2k
Jordi Esteve Spain 43 4.9k 1.3× 2.6k 0.9× 1.8k 1.6× 1.6k 1.6× 1.8k 2.2× 262 7.6k
Arnaud Pigneux France 35 2.8k 0.7× 1.4k 0.5× 765 0.7× 973 1.0× 869 1.1× 161 4.1k
Pierre W. Wijermans Netherlands 24 2.4k 0.6× 1.7k 0.6× 886 0.8× 604 0.6× 576 0.7× 69 3.7k
Claude Gardin France 35 3.2k 0.8× 1.9k 0.7× 750 0.7× 800 0.8× 1.1k 1.4× 123 4.3k

Countries citing papers authored by Pau Montesinos

Since Specialization
Citations

This map shows the geographic impact of Pau Montesinos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pau Montesinos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pau Montesinos more than expected).

Fields of papers citing papers by Pau Montesinos

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pau Montesinos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pau Montesinos. The network helps show where Pau Montesinos may publish in the future.

Co-authorship network of co-authors of Pau Montesinos

This figure shows the co-authorship network connecting the top 25 collaborators of Pau Montesinos. A scholar is included among the top collaborators of Pau Montesinos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pau Montesinos. Pau Montesinos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sargas, Claudia, Marta Llop, Rebeca Rodríguez‐Veiga, et al.. (2025). Feasible and Rapid Screening of IDH1/2 and FLT3-TKD2 Mutations by High-Resolution Melting for Patients with Acute Myeloid Leukemia. Diagnostics. 15(10). 1230–1230.
2.
Ferrara, Felicetto, Klaus Geißler, Priyanka Mehta, Pau Montesinos, & Adriano Venditti. (2025). Unmet needs in patients with acute myeloid leukemia ineligible for intensive approaches: perspectives from a European expert panel. Frontiers in Oncology. 15. 1642472–1642472.
3.
Geller, Ron, Bruno Paiva, Stephanie Sanchez, et al.. (2025). The Rise of Fine-Tuned CAR-Based Therapies Against Acute Myeloid Leukemia. Cancers. 17(24). 3892–3892.
4.
Guerreiro, Manuel, et al.. (2025). CAR-T Cell Therapy for Acute Myeloid Leukemia: Where Do We Stand Now?. Current Oncology. 32(6). 322–322. 1 indexed citations
5.
Daver, Naval, Pau Montesinos, Daniel J. DeAngelo, et al.. (2024). Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody–drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study. The Lancet Oncology. 25(3). 388–399. 34 indexed citations
6.
Ribera, Josep‐María, Josep‐María Ribera, Mireia Morgades, et al.. (2024). Ponalfil trial for adults with Philadelphia chromosome‐positive acute lymphoblastic leukemia: Long‐term results. HemaSphere. 8(4). e67–e67. 10 indexed citations
7.
Daver, Naval, Pau Montesinos, Jessica K. Altman, et al.. (2024). A phase 1b/2 study of pivekimab sunirine (PVEK, IMGN632) in combination with venetoclax/azacitidine for patients with newly diagnosed CD123-positive acute myeloid leukemia.. Journal of Clinical Oncology. 42(16_suppl). TPS6585–TPS6585. 1 indexed citations
8.
Montesinos, Pau, Amir T. Fathi, Stéphane de Botton, et al.. (2024). Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib: pooled analysis from clinical trials. Blood Advances. 8(10). 2509–2519. 7 indexed citations
9.
Lemoli, Roberto M., Pau Montesinos, & Akriti Jain. (2023). Real-world experience with CPX-351 in high-risk acute myeloid leukemia. Critical Reviews in Oncology/Hematology. 185. 103984–103984. 9 indexed citations
10.
11.
12.
Ravandi, Farhad, Hartmut Döhner, Andrew H. Wei, et al.. (2023). Survival outcomes in patients with acute myeloid leukaemia who received subsequent therapy for relapse in QUAZAR AML‐001. British Journal of Haematology. 204(3). 877–886. 2 indexed citations
13.
Caballero‐Velázquez, Teresa, Eduardo Rodríguez‐Arbolí, Enrique Colado, et al.. (2023). Prognostic Value of Measurable Residual Disease in Patients with AML Undergoing HSCT: A Multicenter Study. Cancers. 15(5). 1609–1609. 8 indexed citations
14.
Sekeres, Mikkael A., Pau Montesinos, Jan Novák, et al.. (2023). Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial. Leukemia. 37(10). 2017–2026. 15 indexed citations
15.
Megías‐Vericat, Juan Eduardo, et al.. (2020). Tyrosine kinase inhibitors for acute myeloid leukemia: A step toward disease control?. Blood Reviews. 44. 100675–100675. 21 indexed citations
16.
Cortes, Jörge E., Justin M. Watts, Thomas Prébet, et al.. (2018). FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study. Blood. 132(Supplement 1). 1452–1452. 14 indexed citations
17.
Cid, Ana Rosa, Pau Montesinos, Saturnino Haya, et al.. (2017). Allogeneic hematopoietic cell transplantation in an adult patient with Glanzmann thrombasthenia. Clinical Case Reports. 5(11). 1887–1890. 6 indexed citations
18.
Roboz, Gail J., Pau Montesinos, Dominik Selleslag, et al.. (2016). Design of the Randomized, Phase III, QUAZAR AML Maintenance Trial of CC-486 (Oral Azacitidine) Maintenance Therapy in Acute Myeloid Leukemia. Future Oncology. 12(3). 293–302. 29 indexed citations
19.
Martínez‐Cuadrón, David, Pau Montesinos, Lourdes Cordón, et al.. (2011). Central nervous system involvement at first relapse in patients with acute myeloid leukemia. Haematologica. 96(9). 1375–1379. 19 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Vikram Mathews Breakdown of academic impact, for papers by Lionel Adès Breakdown of academic impact, for papers by Giuseppe Avvisati Breakdown of academic impact, for papers by E Archimbaud Breakdown of academic impact, for papers by R Ohno Breakdown of academic impact, for papers by Stéphane de Botton Breakdown of academic impact, for papers by Jordi Esteve Breakdown of academic impact, for papers by Arnaud Pigneux Breakdown of academic impact, for papers by Pierre W. Wijermans Breakdown of academic impact, for papers by Claude Gardin
Rankless by CCL
2026